Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.

TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis drug, Briumvi.

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing secondary progressive MS, according to data from a late stage trial presented Friday, Sept. 20, at a research congress in Copenhagen. The results confirm topline findings published on Sept. 2.

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.